Beta Drugs Limited — Important, 28-10-2024: Updates

Beta Drugs Limited has been recognized by Forbes Asia as one of the "Best Under a Billion" for the third consecutive year, highlighting its commitment to innovation and operational excellence in oncology and supportive care. The company is expanding its global presence to over 40 countries, with plans to enter new markets in CIS, Africa, and Latin America. Beta Drugs aims for EuGMP certification, enhancing its capability to serve European patients.